Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

There are a handful of patients in DESTINY-Breast03 with active brain metastasis that were enrolled, and they did look and ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

“We are excited to present at EORTC-NCI-AACR with data demonstrating how HMBD-802 can potently treat tumors in T-DXd-insensitive settings whilst maintaining an optimal safety profile. I look forward ...

She focused on 2 FDA-approved antibody drug conjugates (ADCs): trastuzumab deruxtecan (T-DXd; Enhertu; Daiichi Sankyo/AstraZeneca) and sacituzumab govitecan (SG), which have both demonstrated ...

Trastuzumab deruxtecan (T-DXd; Enhertu) is an antibody-drug conjugate used as standard therapy for HER2-positive and HER2-low unresectable or metastatic breast cancer. 1 It is classified by the ...